●
The BenchMark ULTRA PLUS tissue staining
system, with optimised workflow, testing efficiency and environmentally
sustainable features, enables pathologists to provide high-quality,
time-critical results to doctors and patients1.
●
With laboratory diagnostics involved in more
than two-thirds of healthcare decision making, innovative laboratory solutions
that enable an accurate and timely diagnosis are crucial to successful
treatment.
● About 17 million new cases of cancer are diagnosed worldwide each year, and nearly 10 million people die from the disease.2
Johannesburg, - Roche (SIX: RO, ROG; OTCQX: RHHBY)
announced the launch of the BenchMark ULTRA PLUS system, its newest advanced
tissue staining platform. The system enables quick and accurate test results so
clinicians can make timely decisions regarding a patient’s care journey.
“Over one million
cases of cancer are diagnosed in Africa each year2. With many African
communities living in rural areas or far from healthcare centres, waiting for a
diagnosis is often one of the most stressful times. The BenchMark ULTRA PLUS enables
pathologists to provide quick and accurate results that help inform patient
treatment options, timeously.” says Alan Yates Ad-Interim General Manager South
Africa & SADC markets, Roche Diagnostics.
Cancer and other
abnormal cells can be characterised by biochemical markers from within the
cells. By applying chemical solutions to tissue on glass slides with the
BenchMark ULTRA PLUS, a healthcare professional can identify these markers to
determine the presence or absence of key drivers that feed the unhealthy cells
and, in many cases, the type of therapy that could be used to combat them3.
The new BenchMark
ULTRA PLUS system continues the evolution of the BenchMark series, which
revolutionised cancer diagnostics by fully automating processes that used to be
performed manually, one slide at a time.
Lab personnel
will be able to manage their activities more efficiently as a result of
simplified software and streamlined productivity and quality control. These
enhancements can help support the quicker delivery of test results for patients
who are waiting for a diagnosis.
The new system
has several innovations such as new intuitive software, remote monitoring
features, an integrated touchscreen for a more optimised user experience, and a
more environmentally sustainable waste system and product packaging1&4.
The
BenchMark ULTRA PLUS system will be available in South Africa, Zimbabwe,
Zambia, Malawi, Lesotho, Namibia and Mauritius in 2023.
About the BenchMark ULTRA PLUS system
The BenchMark
ULTRA PLUS system (including hardware, software and assays) leverages the
success of the current BenchMark series of IHC/ISH advanced staining platforms.
It is built upon the proven technology of the BenchMark ULTRA system to deliver
an enhanced lab experience. The BenchMark ULTRA PLUS system provides optimised
workflow and flexible solutions, helping the anatomic pathology lab manage
their activities efficiently and confidently, while selecting options that work
best for their lab.
BenchMark ULTRA
was the first advanced staining instrument to provide true, single-piece flow.
BenchMark ULTRA PLUS pushes the envelope even further with its improved VENTANA System Software, which
enhances quality control, inventory management and overall user experience due
to its modern architecture1.
The BenchMark ULTRA PLUS incorporates several additional
innovative features based on customer feedback, including remote monitoring
with a connected device, new indicator lights, a retractable work surface, new
slide drawers (that mitigate fluid ingress/egress), a new integrated
touchscreen and more environmentally friendly waste segregation and
degradation. Sustainable packaging uses 40% fewer raw materials and weighs less to provide a
smaller carbon footprint while being transported. The system is
manufactured using innovative and efficient assembly practices to ensure
product quality and delivery1.
About Roche
Roche is a global pioneer in pharmaceuticals and
diagnostics focused on advancing science to improve people’s lives. The
combined strengths of pharmaceuticals and diagnostics, as well as growing
capabilities in the area of data-driven medical insights help Roche deliver
truly personalised healthcare. Roche is working with partners across the
healthcare sector to provide the best care for each person.
Roche is the
world’s largest biotech company, with truly differentiated medicines in
oncology, immunology, infectious diseases, ophthalmology and diseases of the
central nervous system. Roche is also the world leader in in vitro diagnostics
and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
In recent years, Roche has invested in genomic profiling and real-world data
partnerships and has become an industry-leading partner for medical insights.
Founded in 1896,
Roche continues to search for better ways to prevent, diagnose and treat
diseases and make a sustainable contribution to society. The company also aims
to improve patient access to medical innovations by working with all relevant
stakeholders. More than thirty medicines developed by Roche are included in the
World Health Organization Model Lists of Essential Medicines, among them life-saving
antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth
consecutive year, Roche has been recognised as one of the most sustainable
companies in the Pharmaceuticals Industry by the Dow Jones Sustainability
Indices (DJSI).
The Roche Group,
headquartered in Basel, Switzerland, is active in over 100 countries and in
2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF
12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the
United States, is a wholly owned member of the Roche Group. Roche is the
majority shareholder in Chugai Pharmaceutical, Japan.
No comments :
Post a Comment